Table 1.

Adjuvant Dendritic Cell Immunotherapy trials for cancer treatment.

Description	N. of Trials	Disease(s)	Status	Phase
DCs based adjuvant therapy versus standard of care (radio/chemotherapy)	79	24 Brain tumors; 13 Melanoma; 12 Breast Cancer; 6 Liver/colo-rectal cancer; 4 pancreatic cancer; 20 other.	15 Recruiting; 19 Not (yet) recruiting; 38 completed/terminated; 7 Unknown/withdrawn	3 in phase 3; other phase 1, 2
DCs based adjuvant therapy plus ICI	42	11 Melanoma; 3 brain tumor; 4 Gastric cancer; 4 lung cancer; 3 pancreatic cancers; 5 Myeloma/Lymphoma; 12 other	15 Recruiting; 9 Not (yet) recruiting; 12 completed/terminated; 6 Unknown/withdrawn	5 in phase 3/4; other phase 1, 2
DCs based adjuvant therapy plus other adoptive cells therapy	29	6 Brain tumors; 3 Melanoma; 1 lung; 7 epato/gastrict tract cancer; 4 Myeloma/Lymphoma; 8 other	8 Recruiting; 4 Not (yet) recruiting; 5 completed/terminated; 12 Unknown/withdrawn	2 in phase 3; other phase 1, 2

Searching on clinicaltrial.gov (accessed on 5 November 2021) using the keywords “dendritic cells”, “adjuvant therapy” and “cancer” led to 150 results. The majority of trials (79) involve the use of DCs as an adjuvant therapy in combination with the standard of care; 42 trials out of 150 used DCs in addiction to ICI; 29 trials used DCs with other adoptive cells therapies. Most of the trials focus on diseases such as brain tumors (33) and melanoma (27), followed by myeloma/lymphoma (16) breast cancer (12), liver/colon-rectal cancer (six), gastric cancer (11), pancreatic (seven) and lung cancer (five). The majority of trials are in early phase (1, 2) only 10 out of 150 are in phase 3 or 4. The complete list of trials is reported in Supplementary Materials Table S1.